JOHANNESBURG (Reuters) – The South African government is not planning to buy Merck’s COVID-19 treatment pill molnupiravir because an evaluation score from an advisory committee indicated it would not be cost-effective, senior health official Nicholas Crisp told Reuters.
The country’s health regulator SAHPRA said on Thursday that it had authorised use of molnupiravir.
(Reporting by Alexander Winning; Editing by Olivia Kumwenda-Mtambo)
Islanders’ Patrick Roy calls Ilya Sorokin his Ferrari, Semyon Varlamov his Cadillac
Will Power denies participating in Penske cheating scandal. Silence from Josef Newgarden
Pickleball to take over NYC: Billie Jean King National Tennis Center, Queens to host 2024 New York City Open in May
Not every WNBA draft pick will make her team’s roster. Here’s why
French Open to reveal second retractable roof court at Roland Garros ahead of Olympics
South Philadelphia High School placed on lockdown after ammo found
Study says it’s likely a warmer world made deadly Dubai downpours heavier
Flooding in Tanzania has killed 155 people as heavy rains continue in Eastern Africa
A Chinese ship remains the focus of the investigation into Baltic Sea gas pipeline damaged last year
Satellite photos show new port construction in Gaza Strip for US-led aid operation
UN report says 282 million people faced acute hunger in 2023, with the worst famine in Gaza
Malaria is still killing people in Kenya, but a vaccine and local drug production may help
US births fell last year, marking an end to the late pandemic rebound, experts say
US abortion battle rages on with moves to repeal Arizona ban and a Supreme Court case
